New Oral Immunotherapy for Grass Allergies Approved

The FDA has approved Grastek, a second sublingual immunotherapy to 
treat grass pollen allergies. (The first sublingual immunotherapy for 
grass allergies, Oralair, was approved earlier this month.) The new 
tablet contains Timothy grass extracts and is indicated for patients 
aged 5 to 65 years.

In December 2013, FDA advisers called for postapproval studies to test 
Grastek’s safety in children aged 5 to 11 years, citing side effects 
such as lip swelling and oral blistering.

Reuters story (Free)
By Kristin J. Kelley

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s